Literatur
-
1
Burns D N, Landesman S, Wright D J. et al .
Influence of other
maternal variables on the relationship between maternal virus load
and mother-to-infant transmission of human immunodeficiency virus
type 1.
J Infect Dis.
1997;
175
1206-1210
-
2
Frenkel L M, Cowles M K, Shapiro D E. et al .
Analysis of the Maternal
Components of the AIDS Clinical Trial Group 076 Zidovudine Regimen
in the Prevention of Mother-to-Infant Transmission of Human Immunodeficiency
Virus Type 1.
J Infect Dis.
1997;
175
971-974
-
3
Landesmann S H, Kalish L A, Burns D N. et al .
Obstetrical Factors and
The Transmission of Human Immunodeficiency Virus Type 1 from Mother
to Child.
N Engl J Med.
1996;
334
1617-1623
-
4
Mandelbrot L, Le Chenadec J, Berrebi A. et al .
Perinatal HIV-1 Transmission: Interaction
between Zidovudine Prophylaxis and Mode of Delivery in the French
Perinatal Cohort.
JAMA.
1998;
280
55-60
-
5
Mayaux M J, Dussaix E, Isopet J. et al .
Maternal Virus Load during Pregnancy and
Mother-to-Child Transmission of Human Immunodeficiency Virus Type
1: The French Perinatal Cohort Studies.
J Infect Dis.
1997;
175
172-175
-
6
Pitt J, Brambilla D, Reichelderfer P. et al .
Maternal Immunologic and Virologic Risk
Factors for Infant Human Immunodeficiency Virus Type 1 Infection:
Findings from the Women and Infants Transmission Study.
J
Infect Dis.
1997;
175
567-575
-
7
Rokos K, Wang H, Seeger J. et
al .
Transport of Viruses Through Fetal Membranes: An
In Vitro Model of Perinatal Transmission.
J Med Virology.
1998;
54
313-319
-
8
Sperling R S, Shapiro D E, Coombs R W. et al .
Maternal Viral Load, Zidovudine
Treatment, and the Risk of Transmission of Human Immunodeficiency
Virus Type 1 from Mother to Infant.
N Engl J Med.
1996;
335
1621-1629
-
9
The European Collaborative
Study .
Vertical transmission of HIV-1: maternal immune
status and obstetric factors.
AIDS.
1996;
10
1675-1681
-
10
The European Collaborative
Study .
Immunological markers in HIV-infected pregnant
women.
AIDS.
1997;
11
1859-1865
-
11
Kind Ch, Rudin Ch, Siegrist C. et al .
Prevention of vertical HIV transmission:
additive protective effect of elective Cesarean section and zidovudine
prophylaxis.
AIDS.
1998;
12
205-210
-
12 Lutz-Friedrich R, Buchholz B, Klarmann D. et al .Combining ZVD treatment and elective Cesarean
section reduces the vertical transmission of HIV-1 below 3 % in
the German perinatal cohorts. 12th World AIDS Conference
Geneva, June 28-July 3 Poster 23 291 1998
-
13
Schäfer A PA.
Die HIV-Infektion in Geburtshilfe und Gynäkologie.
Gynäkologe.
1996;
29
129-137
-
14 Schäfer A, Friese K, Lauper U. et al .Influence of cesarean section before parturition
and antiretroviral prophylaxis on the materno-fetal transmission
of HIV. 12th World AIDS Conference Geneva, June 28-July
3 1998, Poster LB 12 466 1998
-
15
CDC .
Recommendations
of the U-S. Public Health Service Task Force on the Use of Zidovudine
to Reduce Perinatal Transmission of Human Immunodeficiency Virus.
MMWR.
1994;
43
RR-11
-
16
Connor E M, Sperling R S, Gelber R. et al .
Reduction of Maternal-Infant Transmission
of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment.
N
Engl J Med.
1994;
331
1173-1180
-
17
Maguire A, Sanchez E, Fortuny C. et al .
Potential risk factors for vertical HIV-1
transmission in Catalonia, Spain: the protective role of Cesarean section.
AIDS.
1997;
11
1851-1857
-
18 Semprini A E. An international randomised trial of mode
of delivery in HIV infected women. 12th World AIDS
Conference Geneva, June 28-July 3 1998 1998: Poster LB 23 599
-
19
The International Perinatal
HIV Group .
The mode of delivery and the risk of vertical
transmission of human immunodeficiency virus type 1 - a meta-analysis
of 15 prospective cohort studies.
N Eng J Med.
1999;
340
977-987
-
20
Ferrazin A, de Maria A, Gotta C. et al .
Zidovudine therapy of HIV-1 Infection During
Pregnancy: Assessment of the Effect on the Newborns.
J
Acquired Immune Deficiency Syndromes.
1993;
6
376-379
-
21
OŽSullivan M, Boyer P, Scott G. et
al .
The pharmacokinetics and safety of zidovudine in
the third trimester of pregnancy for women infected with human immunodeficiency
virus and their infants: Phase I Acquired Immunodeficiency Syndrome
Clinical Trials Group study (protocol 082).
Am J Obstet
Gynecol.
1993;
168
1510-1516
-
22
Scalfaro P, Chesaux J J, Buchwalder P A. et al .
Severe transient
neonatal lactic acidosis during prophylactic zidovudine treatment.
Intensive
Care Med.
1998;
24
247-250
-
23 Antiretroviral Pregnancy
Registry .International Interim Report for Didanosine,
Indinavir, Lamivudine, Saquinavir, Stavudine, Zalcitabine and Zidovudine. 1
January 1989-31 December 1997
-
24
Meng Q, Walker D M, Olivero O A. et al .
Zidovudine-didanosine coexposure
potentiates DNA incorporation of zidovudine and mutagenesis in human
cells.
Proc Natl Acad Sci USA.
2000;
97
1266-12 671
-
25
Poirier M C, Patterson T A, Slikker W, Olivero O A.
Incorporation
of 3Ž-Azido-3Ž-Deoxythymidine (AZT) into fetal
DNA and fetal tissue distribution of drug after infusion of pregnant
late-term rhesus macaques with a human-equivalent AZT dose.
J
Acquir Imm Def Syn.
1999;
22
477-483
-
26
Wahn V.
Routinemäßige
Gabe von Zidovudin an HIV-infizierte Schwangere.
Dt Ärztebl.
1995;
92
A3397-3398
-
27 Moodley D. et al .The SAINT trial: Nevirapine versus zidovudine + lamivudine
in prevention of peripartum HIV transmission. 13. World
AIDS Conference, Durban 2000 Abstr. # LbOr2
-
28 Owor M, Deseyve M, Duefield C. et al .The one year safety and efficacy data of
the HIVNET 012 trial. 13. World-AIDS-Conference, Durban 2000 Abstr. # LbOr1
-
29
Goldstein. et
al .
Association between HIV in pregnancy and antiretroviral therapy,
including protease inhibitors and low birth weight infants.
Infect
Dis Obstet Gynecol.
2000;
8
94-98
-
30
Lorenzi. et
al. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy
Study, and the Swiss Neonatal HIV Study .
Antiretroviral
therapies in pregnancy: maternal, fetal and neonatal effects.
AIDS.
1998;
12
F241-247
-
31
Blanche S, Tardieu M, Rustin P. et al .
Persistent mitochondrial dysfunction and
perinatal exposure to antiretroviral nucleoside analogues.
Lancet.
1999;
354
1084-1089
-
32
CDC Public Health Service
Task Force .
Recommendations for the Use of Antiretroviral
Drugs in Pregnant Women Infected with HIV-1 for Maternal Health
and for Reducing Perinatal HIV-1 Transmission in the United States.
MMWR.
1998;
47
RR2
-
33
CDC .
Report
of the NIH Panel to Define Principles of Therapy of HIV Infection
and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults
and Adolescents.
MMWR.
1998;
47
RR-5
-
34
Fischer C, Rosenwald V, Haarewood L. et al .
Antiretrovirals during pregnancy in HIV-1-positive
women in New York City.
Lancet.
1998;
351
1029-1030
-
35 Beckermann K, Benson M, Dahid S. et al .Control of maternal HIV-1 disease during
pregnancy. 12th World AIDS Conference Geneva, June
28-July 3 1998 1998 Poster 12 151
-
36 Kramer F, Stek A, Homans J. et
al .Combination therapy with nevirapine, zidovudine
and a second nucleoside analog during pregnancy. 12th World
AIDS Conference Geneva, June 28-July 3 1998 1998 Poster 12 152
-
37
Minkoff H, Augenbraun M.
Antiretroviral therapy
for pregnant women.
Am J Obstet Gynecol.
1997;
176
478-489
-
38
Deutsch-Österreichische
Empfehlungen zur antiretroviralen Therapie der HIV-Infektion.
Dtsch
Med Wochenschr.
2003;
128
(Suppl.1)
S7-S16
-
39
Lindgren S, Martin C, Anzen B. et al .
Pattern of HIV viraemia and CD4 levels
in relation to pregnancy in HIV-1 infected women.
Scand
J Infect Dis.
1996;
28
1057-1060
-
40
Rich K C, Siegel J N, Jennings C. et al .
CD4+ lymphocytes in perinatal
human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced
immune depression in uninfected and HIV-infected women.
J Infect
Dis.
1995;
172
1221-1227
-
41 Rublein J, Calhoun E, Biddle A. et al .Prevalence of antiretroviral resistance
in women of child-bearing potential. 13. World-AIDS-Conference, Durban 2000 Abstr. # MoPe2206
-
42
Welles S L, Pitt J, Colgrove R. and The Women and Infants Transmission Study Group .
HIV-1
genotypic zidovudine drug resistance and the risk of maternal-infant
transmission in the Women and Infants Transmission Study.
AIDS.
2000;
14
263-271
-
43
Eastman P S, Shapiro D E, Coombs R W. et al .
Maternal Viral Genotypic
Zidovudine Resistance and Infrequent Zidovudine Therapy to Prevent
Perinatal Transmission of Human Immunodeficiency Virus Type 1 in
Pediatric Clinical Trial Protocol 076.
J Infect Dis.
1998;
177
557-564
-
44
Jackson J B, Becker-Pergola G, Guay L A. et al .
Identification of the K103N resistance
mutation in Ugandan women receiving nevirapine to prevent HIV-1
vertical transmission.
AIDS.
2000;
14
F111-F115
-
45 Sustiva Capsules Product
Monograph 1998
-
46 BMS Warning Letter vom
5. Januar 2001 2001
-
47
Hayashi S, Beckerman K, Homma M. et al .
Pharmacokinetics of indinavir in HIV-positive
pregnant women.
AIDS.
2000;
14
1061-1062
-
48
Qian M, Bui T, Ho R JY. et al .
Metabolism of 3Ž-Azido-3Ž-Deoxythymidine (AZT)
in Human Placental Trophopblasts and Hofbauer Cells.
Biochemical
Pharmacology.
1994;
48
383-389
-
49
Sandberg J A, Slikker W.
Developmental pharmacology
and toxicology of anti-HIV therapeutic agents: dideoxynucleosides.
FASEB
J.
1995;
9
1157-1164
-
50
Morris A B, Cu-Uvin S, Harwell J I. et al .
Multicenter review of protease inhibitors
in 89 pregnancies.
J Acquir Imm Deficiency Syndr.
2000;
25
306-311
-
51 Larsen W J. Human
Embryology. New York: Churchill Livingstone 1993
-
52 Spielmann H, Steinhoff R, Schaefer C. et al .Arzneiverordnung in Schwangerschaft und
Stillzeit. 5. Aufl., Stuttgart, Gustav Fischer 1998
-
53 Wilson J D, Frazer F C. Handbook of
Teratology,. New York: Plenum Press 1977 Vol.
I
-
54 Blattner W, Cooper E, Charurat M. et al .Effectiveness of potent anti-retroviral
therapies on reducing perinatal transmission of HIV-1. 13.
World AIDS Conference, Durban 2000 Abstr. # LbOr4
-
55
Chuachoowong R, Shaffer N, Siriwasin W. et al .
Short-course antenatal zidovudine reduces
both cervicovaginal human immunodeficiency virus type 1 RNA levels
and risk of perinatal transmission.
J Inf Dis.
2000;
181
99-106
-
56
Garcia. et
al .
Maternal levels of plasma human immunodeficiency
virus type 1 RNA and the risk of perinatal transmission.
N
Eng J Med.
1999;
341
394-402
-
57
Mofenson L M. et al .
Risk factors for perinatal transmission
of human immunodeficiency virus type 1 in women treated with zidovudine.
N
Eng J Med.
1999;
341
385-393
-
58
Newell M -L. et al .
Maternal viral load and vertical transmission
of HIV-1: an important factor but not the only one.
AIDS.
1999;
13
1377-1385
-
59
Shaffer N, Roongpisuthipong A, Siriwasin W. et al .
Maternal virus load and perinatal human
immunodeficiency virus type 1 subtype E transmission, Thailand.
J
Inf Dis.
1999;
179
590-599
-
60
European Collaborative Study
and the Swiss Mother + Child HIV Cohort Study .
Combination
antiretroviral therapy and duration of pregnancy.
AIDS.
2000;
14
2913-2920
-
61
Grosch-Wörner I, Sch& auml;fer A, Obladen M. et al .
An effective
and safe protocol involving zidovudine and caesarean section to
reduce vertical transmission of HIV-1 infection.
AIDS.
2000;
14
2903-2911
-
62
Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Kücherer C.
Frequency of genotypic and phenotypic drug-resistant
HIV-1 among therapy-naive patients of the German Seroconverter Study.
J Acquir
Imm Def Syndr.
2001;
26
266-273
-
63
Lallemant M, Jourdain G, Le C oeur
S. et al .
A trial of shortened zidovudine regimens
to prevent mother-to-child transmission of human immunodeficiency
virus type 1.
N Eng J Med.
2000;
343
982-991
-
64
Burns D N, Landesman S, Muenz L R. et al .
Cigarette smoking, premature rupture of
membranes and vertical transmission of HIV1 among women with low
CD4+ levels.
J Acquir Immune Deficiency Syndr.
1994;
7
718-726
-
65
Mirochnick M, Fenton T, Gagnier. P
et al. Pediatric AIDS Clinical Trials Group Protocol 250 Team .
Pharmacokinetics
of nevirapine in human immunodeficiency virus type 1-infected pregnant
women and their neonates.
J Infect Dis.
1998;
178
368-374
-
66
Moodley J, Moodley D, Pillay K. et al .
Pharmacokinetics and antiretroviral activity
of lamivudine alone or when coadministered with zidovudine in human
immunodeficiency virus type 1-infected pregnant women and their
offspring.
J Infect Dis.
1998;
178
1327-1333
-
67 Read J. Duration
of ruptured membranes and vertical transmission of HIV-1: a metaanalysis
from fifteen prospective cohort studies. 7th Conference
on Retroviruses and Opportunistic Infections, January30- February2,
2000, San Francisco 2000 Abstract
659
-
68
Deutsch-Österreichische
Empfehlungen zur postexpositionellen Prophylaxe der HIV-Exposition.
Dtsch
Med Wochenschr.
2003;
128
(Suppl.1)
S36-S50
-
69
Taylor G P, Lyall E GH, Back D, Ward C, Tudor-Williams G.
Pharmacological
implications of lengthened in-utero exposure to nevirapine.
Lancet.
2000;
355
213-215
-
70
Wade N A, Birkhead G S, Warren B L. et al .
Abbreviated regimens of
zidovudine prophylaxis and perinatal transmission of the human immunodeficiency
virus.
N Engl J Med.
1998;
339
1409-1414
-
71
Guay L A, Musoke P, Fleming T. et al .
Intrapartum and neonatal single dose nevirapine
compares with zidovudine for prevention of mother-to-child transmission
of HIV-1 in Kampala, Uganda. HIVNET 012 randomized trial.
Lancet.
1999;
354
795-802
-
72 Aids von A bis Z;. Bundeszentrale
für gesundheitliche Aufklärung, Köln: Neuauflage 1999
-
73 Der heutige Wissensstand. Deutsche
AIDS-Hilfe e. V. 26. überarbeitete Auflage, Dezember
2000 2000
-
74
Marcus U.
AIDS
und HIV-Infektionen bei Frauen und Kindern in Deutschland.
Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz.
1999;
42
553-557
-
75
Ioannidis J PA, Abrams E J, Ammann A, Bulterys M, Goedert J J, Gray L, Korber B T, Mayaux M J, Mofenson L M, Newell M -L, Shapiro D E, Teglas J P, Wilfert C M.
Perinatal
transmission of human immunodeficiency virus type 1 by pregnant
women with RNA virus loads < 1000 copies/ml.
J
Inf Dis.
2001;
183
539-545
-
76
Gaillard P, Verhofstede C, Mwanyumba F. et al .
Exposure to HIV-1 during delivery and mother-to-child
transmission.
AIDS.
2000;
14
2341-2348
-
77
Halpern M T, Read J S, Ganoczy D A, Harris D R.
Cost-effectiveness
of cesarean section delivery to prevent mother-to-child transmission
of HIV-1.
AIDS.
2000;
14
691-700
-
78
Mandelbrot L, Burgard M, Teglas J -P. et al .
Frequent detection of HIV-1 in the gastric
aspirates of neonates born to HIV-infected mothers.
AIDS.
1999;
13
2143-2149
-
79
Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J. et al .
Effect of breastfeeding and formula feeding
on Transmission of HIV-1.
JAMA.
2000;
283
1167-1174
Dr. Bernd Buchholz
Leiter der HIV-Ambulanz der Universitätsklinik
Mannheim, Klinikum Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Phone: 0621-383-2504
Fax: 0621-383-1988
Email: bernd.buchholz@kikli.ma.uni-heidelberg.de
